Pharmabiz22h
icometrix’s AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment
icometrix, a global leader in AI-driven software, announced that on November 7, 2024, the US Food and Drug Administration (FDA) granted the company clearance for icobrain aria, the first and only AI ...
Pharmabiz1d
New investment from the ADDF’s Diagnostics Accelerator leads efforts to develop standardization materials for leading diagnostic biomarker
New investment from the ADDF’s Diagnostics Accelerator leads efforts to develop standardization materials for leading diagnostic biomarker: New York Saturday, November 16, 2024, ...
Pharmabiz1d
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease
Eisai Co., Ltd. and Biogen Inc., a leading biotechnology company, announced a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Pharmabiz1d
Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development
Critical infrastructure in biopharma and medical devices plays a vital role in enabling innovation, bolstering research and development, and ensuring the production of novel drugs and products. It ...
Pharmabiz1d
Dr. Nimmy VS of Vaidyaratnam Ayurveda College wins first prize in All India Ayurveda Thesis Competition 2024
Peethaambaran Kunnathoor, Chennai Saturday, November 16, 2024, 08:00 Hrs [IST] ...
Pharmabiz1d
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...
Pharmabiz1d
Indian healthcare industry makes significant strides in epilepsy treatment with access to new drugs & surgical options
Nandita Vijayasimha, Bengaluru Saturday, November 16, 2024, 08:00 Hrs [IST] ...
Pharmabiz1d
New technologies and treatments revolutionizing diabetes care: Dr Ajay Aggarwal
New technologies and treatments revolutionizing diabetes care: Dr Ajay Aggarwal: Shardul Nautiyal, Mumbai Saturday, November 16, 2024, 08:00 Hrs [IST] As diabetes continues to ris ...
Pharmabiz1d
WHO & US CDC new estimates show measles cases surge worldwide, infecting 10.3 million people in 2023
WHO & US CDC new estimates show measles cases surge worldwide, infecting 10.3 million people in 2023: Geneva Saturday, November 16, 2024, 10:00 Hrs [IST] Worldwide, there were an ...
Pharmabiz1d
NCCE recommends reports generated by automatic analyser can be signed by technician
NCCE recommends reports generated by automatic analyser can be signed by technician: Our Bureau, New Delhi Saturday, November 16, 2024, 08:00 Hrs [IST] The National Council for Cl ...
Pharmabiz1d
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced that the first participant has been vaccinated in a ...
Pharmabiz1d
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions: Woburn, Massachusetts Saturday, November 16, 2024, 17:00 Hrs ...